RxDoctor Payments Data

Andrea Arteaga Useche, MD

Cornea and External Diseases Specialist · Chicago, ILNPI 1154826584

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,089 and has fallen 60.5% since, to $430 in 2025.

$1,561in general payments, 2019–2025

Across 57 payments — averaging $27.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$374
  • Glaukos Corporation$302
  • Harrow Eye, LLC$232
  • AbbVie$177
  • Tarsus Pharmaceuticals, Inc.$148
  • Mallinckrodt Hospital Products Inc.$123
  • plus $207 from 5 others

What the payments were for

  • Food & beverage$1,561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cornea and external diseases specialist providers in Illinoisto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$86,819
Medicare patients
312
Services billed
627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost27$15,719
Prednisolone Acetate173$10,459
Fluorometholone30$3,158
Ketorolac Tromethamine156$3,028
ErythromycinErythromycin Base295$2,896
Ofloxacin133$1,301
Latanoprost124$1,195
ValacyclovirValacyclovir Hcl18$952
Tobramycin-DexamethasoneTobramycin/Dexamethasone14$565
Brimonidine Tartrate28$509
Doxycycline Hyclate12$473
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat24$428
Doxycycline Monohydrate14$382
Timolol Maleate36$361
Dorzolamide Hcl21$268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$177$15,71927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Illinoison file to place this against a meaningful peer group, so we don't.

Other cornea and external diseases specialist in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →